402 related articles for article (PubMed ID: 28323900)
21. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
22. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
23. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
24. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
Fleury L; Gerus M; Lavigne AC; Richard-Foy H; Bystricky K
Oncogene; 2008 Jul; 27(29):4075-85. PubMed ID: 18317449
[TBL] [Abstract][Full Text] [Related]
25. Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment.
Krushkal J; Zhao Y; Hose C; Monks A; Doroshow JH; Simon R
Clin Epigenetics; 2016; 8():73. PubMed ID: 27347216
[TBL] [Abstract][Full Text] [Related]
26. Aloe vera inhibits proliferation of human breast and cervical cancer cells and acts synergistically with cisplatin.
Hussain A; Sharma C; Khan S; Shah K; Haque S
Asian Pac J Cancer Prev; 2015; 16(7):2939-46. PubMed ID: 25854386
[TBL] [Abstract][Full Text] [Related]
27. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise A; Momparler RL
Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions.
Vijayaraghavalu S; Peetla C; Lu S; Labhasetwar V
Mol Pharm; 2012 Sep; 9(9):2730-42. PubMed ID: 22817326
[TBL] [Abstract][Full Text] [Related]
29. Growth factors and chemotherapeutic modulation of breast cancer cells.
Ciftci K; Su J; Trovitch PB
J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904
[TBL] [Abstract][Full Text] [Related]
30. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
31. The effect of chemotherapeutic agents on telomere length maintenance in breast cancer cell lines.
Motevalli A; Yasaei H; Virmouni SA; Slijepcevic P; Roberts T
Breast Cancer Res Treat; 2014 Jun; 145(3):581-91. PubMed ID: 24807106
[TBL] [Abstract][Full Text] [Related]
32. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
[TBL] [Abstract][Full Text] [Related]
33. Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Scholpa NE; Kolli RT; Moore M; Arnold RD; Glenn TC; Cummings BS
Chem Biol Interact; 2016 Oct; 258():21-9. PubMed ID: 27543423
[TBL] [Abstract][Full Text] [Related]
34. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells.
Teixeira C; Reed JC; Pratt MA
Cancer Res; 1995 Sep; 55(17):3902-7. PubMed ID: 7641210
[TBL] [Abstract][Full Text] [Related]
35. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
36. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
[TBL] [Abstract][Full Text] [Related]
37. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
38. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
39. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.
Lee MT; Ho SM; Tarapore P; Chung I; Leung YK
Neoplasia; 2013 Nov; 15(11):1262-71. PubMed ID: 24339738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
